Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$782.17 -0.7%	$755.88	$510.05 ▼ $934.62	$48.64B	0.46	307,650 shs	354,205 shs
AXSM Axsome Therapeutics	$217.38 -1.3%	$173.69	$96.09 ▼ $234.29	$11.19B	0.59	911,931 shs	574,229 shs
AZTA Azenta	$19.22 +3.5%	$23.17	$17.11 ▼ $41.73	$885.31M	1.43	1.22 million shs	1.02 million shs
GS The Goldman Sachs Group	$936.72 +1.2%	$870.56	$565.78 ▼ $984.70	$276.27B	1.28	1.95 million shs	1.66 million shs
VCEL Vericel	$33.46 -4.8%	$33.93	$28.95 ▼ $45.97	$1.70B	1.15	580,539 shs	1.54 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-0.65%	-0.17%	-2.29%	-3.61%	+25.63%
AXSM Axsome Therapeutics	-1.11%	+5.25%	+21.51%	+19.08%	+96.09%
AZTA Azenta	+3.50%	-22.84%	-15.18%	-33.08%	-24.02%
GS The Goldman Sachs Group	+1.27%	+1.45%	+3.54%	+0.78%	+69.70%
VCEL Vericel	-4.75%	-5.93%	-0.39%	-7.54%	-17.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARGX argenex	$782.17 -0.7%	$755.88	$510.05 ▼ $934.62	$48.64B	0.46	307,650 shs	354,205 shs
AXSM Axsome Therapeutics	$217.38 -1.3%	$173.69	$96.09 ▼ $234.29	$11.19B	0.59	911,931 shs	574,229 shs
AZTA Azenta	$19.22 +3.5%	$23.17	$17.11 ▼ $41.73	$885.31M	1.43	1.22 million shs	1.02 million shs
GS The Goldman Sachs Group	$936.72 +1.2%	$870.56	$565.78 ▼ $984.70	$276.27B	1.28	1.95 million shs	1.66 million shs
VCEL Vericel	$33.46 -4.8%	$33.93	$28.95 ▼ $45.97	$1.70B	1.15	580,539 shs	1.54 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARGX argenex	-0.65%	-0.17%	-2.29%	-3.61%	+25.63%
AXSM Axsome Therapeutics	-1.11%	+5.25%	+21.51%	+19.08%	+96.09%
AZTA Azenta	+3.50%	-22.84%	-15.18%	-33.08%	-24.02%
GS The Goldman Sachs Group	+1.27%	+1.45%	+3.54%	+0.78%	+69.70%
VCEL Vericel	-4.75%	-5.93%	-0.39%	-7.54%	-17.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARGX argenex	2.92	Moderate Buy	$1,017.78	30.12% Upside
AXSM Axsome Therapeutics	2.90	Moderate Buy	$251.26	15.59% Upside
AZTA Azenta	2.38	Hold	$39.50	105.52% Upside
GS The Goldman Sachs Group	2.36	Hold	$942.24	0.59% Upside
VCEL Vericel	2.63	Moderate Buy	$55.40	65.57% Upside

Current Analyst Ratings Breakdown

Latest GS, VCEL, ARGX, AZTA, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/8/2026	GS The Goldman Sachs Group	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B-) ➝ Hold (C+)
5/8/2026	GS The Goldman Sachs Group	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$765.00 ➝ $930.00
5/8/2026	VCEL Vericel	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$64.00
5/8/2026	ARGX argenex	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,120.00 ➝ $1,135.00
5/8/2026	ARGX argenex	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,247.00 ➝ $1,260.00
5/7/2026	GS The Goldman Sachs Group	Dbs Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$890.00 ➝ $1,050.00
5/6/2026	AZTA Azenta	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$44.00 ➝ $33.00
5/6/2026	GS The Goldman Sachs Group	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target		$930.00 ➝ $940.00
5/5/2026	AXSM Axsome Therapeutics	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$280.00
5/5/2026	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$225.00 ➝ $255.00
5/5/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$242.00 ➝ $302.00

(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARGX argenex	$4.25B	11.45	$21.34 per share	36.66	$118.34 per share	6.61
AXSM Axsome Therapeutics	$638.50M	17.52	N/A	N/A	$1.06 per share	205.08
AZTA Azenta	$596.33M	1.48	$1.81 per share	10.60	$33.75 per share	0.57
GS The Goldman Sachs Group	$125.10B	2.21	$64.56 per share	14.51	$369.75 per share	2.53
VCEL Vericel	$292.09M	5.83	$0.56 per share	60.23	$6.99 per share	4.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARGX argenex	$1.29B	$19.52	34.83	24.53	1.28	31.31%	33.28%	28.16%	7/23/2026 (Estimated)
AXSM Axsome Therapeutics	-$183.17M	-$3.73	N/A	53.94	N/A	-26.59%	-267.16%	-28.53%	N/A
AZTA Azenta	-$55.76M	-$3.96	N/A	N/A	N/A	-30.49%	1.23%	1.02%	N/A
GS The Goldman Sachs Group	$17.18B	$54.72	17.12	14.24	1.21	14.13%	16.53%	0.97%	7/14/2026 (Estimated)
VCEL Vericel	$16.52M	$0.42	79.67	43.45	N/A	7.35%	6.41%	4.61%	N/A

Latest GS, VCEL, ARGX, AZTA, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2026	Q1 2026	ARGX argenex	$5.74	$5.52	-$0.22	$5.52	$1.44 billion	$1.31 billion
5/7/2026	Q1 2026	VCEL Vericel	-$0.15	-$0.12	+$0.03	-$0.12	$63.68 million	$68.43 million
5/6/2026	Q2 2026	AZTA Azenta	$0.1228	-$0.04	-$0.1628	-$3.49	$148.47 million	$144.80 million
5/4/2026	Q1 2026	AXSM Axsome Therapeutics	-$0.85	-$1.26	-$0.41	-$1.26	$191.10 million	$191.20 million
4/13/2026	Q1 2026	GS The Goldman Sachs Group	$15.92	$17.55	+$1.63	$17.55	$16.66 billion	$17.23 billion
2/26/2026	Q4 2025	ARGX argenex	$6.05	$8.02	+$1.97	$8.02	$1.30 billion	$1.32 billion
2/26/2026	Q4 2025	VCEL Vericel	$0.45	$0.45	N/A	$0.45	$92.66 million	$92.92 million
2/23/2026	Q4 2025	AXSM Axsome Therapeutics	-$0.70	-$0.56	+$0.14	-$0.56	$191.33 million	$196.00 million
2/14/2026	Q4 2025	ARGX argenex	N/A	$8.02	N/A	$8.02	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARGX argenex	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
AZTA Azenta	$0.10	0.52%	-100.00%	N/A	N/A
GS The Goldman Sachs Group	$18.00	1.92%	+22.87%	32.89%	13 Years
VCEL Vericel	N/A	N/A	N/A	N/A	N/A

Latest GS, VCEL, ARGX, AZTA, and AXSM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/13/2026	GS The Goldman Sachs Group	quarterly	$4.50	2.02%	6/1/2026	6/1/2026	6/29/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARGX argenex	N/A	5.23	4.87
AXSM Axsome Therapeutics	2.27	1.39	1.48
AZTA Azenta	N/A	2.83	2.61
GS The Goldman Sachs Group	2.89	0.63	0.66
VCEL Vericel	N/A	5.18	4.68

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARGX argenex	60.32%
AXSM Axsome Therapeutics	81.49%
AZTA Azenta	99.08%
GS The Goldman Sachs Group	71.21%
VCEL Vericel	N/A

Insider Ownership

Company	Insider Ownership
ARGX argenex	2.43%
AXSM Axsome Therapeutics	20.60%
AZTA Azenta	10.90%
GS The Goldman Sachs Group	0.55%
VCEL Vericel	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARGX argenex	1,863	62.19 million	60.68 million	Optionable
AXSM Axsome Therapeutics	380	51.46 million	40.86 million	Optionable
AZTA Azenta	3,000	46.06 million	41.04 million	Optionable
GS The Goldman Sachs Group	47,400	295.01 million	293.38 million	Optionable
VCEL Vericel	300	50.93 million	47.06 million	Optionable

GS, VCEL, ARGX, AZTA, and AXSM Headlines

Recent News About These Companies

Vericel (NASDAQ:VCEL) Shares Down 9.1% - Time to Sell?

4 hours ago | americanbankingnews.com

Vericel Corporation 2026 Q1 - Results - Earnings Call Presentation

May 9 at 7:41 PM | seekingalpha.com

Analysts Have Made A Financial Statement On Vericel Corporation's (NASDAQ:VCEL) First-Quarter Report

May 9 at 5:57 PM | finance.yahoo.com

Vericel (VCEL) Q1 2026 Earnings Transcript

May 9 at 7:55 AM | finance.yahoo.com

Vericel Q1 Earnings Call Highlights

May 9 at 2:06 AM | marketbeat.com

Vericel Earnings Call Signals Accelerating Growth and Margins

May 8 at 9:50 PM | tipranks.com

Vericel (NASDAQ:VCEL) Trading Down 9.1% - What's Next?

May 8 at 1:22 PM | marketbeat.com

Vericel Corporation (VCEL) Q1 2026 Earnings Call Transcript

May 7 at 12:00 AM | seekingalpha.com

Vericel (NASDAQ:VCEL) Posts Earnings Results, Beats Estimates By $0.03 EPS

May 7 at 11:04 PM | marketbeat.com

Vericel Corporation (VCEL) Reports Q1 Loss, Beats Revenue Estimates

May 7 at 12:16 PM | zacks.com

Vericel (NASDAQ:VCEL) Shares Gap Up on Strong Earnings

May 7 at 10:19 AM | marketbeat.com

Vericel Corporation Reports 30% Revenue Growth to $68.4 Million in Q1 2026, Raises Full-Year Guidance to $326-$336 Million

May 7 at 8:11 AM | quiverquant.comQ

Vericel Reports First Quarter 2026 Financial Results and Raises Full-Year Financial Guidance

May 7 at 7:45 AM | globenewswire.com

Vericel Q1 2026 earnings preview

May 7 at 3:43 AM | msn.com

Wall Street Analysts Think Vericel (VCEL) Could Surge 53.42%: Read This Before Placing a Bet

May 4, 2026 | zacks.com

Vericel Corporation (NASDAQ:VCEL) Receives $55.40 Average PT from Analysts

May 3, 2026 | americanbankingnews.com

Vericel Shareholders Reaffirm Board, Pay Plan, Auditor

May 1, 2026 | tipranks.com

Conestoga Capital Advisors LLC Acquires 79,278 Shares of Vericel Corporation $VCEL

May 1, 2026 | marketbeat.com

Vericel Annual Meeting: Shareholders Elect Seven Directors, Approve Say-on-Pay and PwC Auditor

May 1, 2026 | marketbeat.com

Vericel (VCEL) Expected to Announce Earnings on Thursday

April 30, 2026 | marketbeat.com

Vericel Corporation (NASDAQ:VCEL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 28, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GS, VCEL, ARGX, AZTA, and AXSM Company Descriptions

argenex NASDAQ:ARGX

$782.17 -5.14 (-0.65%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$797.88 +15.71 (+2.01%)

As of 05/8/2026 07:41 PM Eastern

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Axsome Therapeutics NASDAQ:AXSM

$217.38 -2.84 (-1.29%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$217.62 +0.25 (+0.11%)

As of 05/8/2026 07:57 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Azenta NASDAQ:AZTA

$19.22 +0.65 (+3.50%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$18.68 -0.54 (-2.83%)

As of 05/8/2026 05:26 PM Eastern

Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.

The Goldman Sachs Group NYSE:GS

$936.72 +10.85 (+1.17%)

Closing price 05/8/2026 03:59 PM Eastern

Extended Trading

$936.25 -0.47 (-0.05%)

As of 05/8/2026 07:53 PM Eastern

The Goldman Sachs Group, Inc., a financial institution, provides a range of financial services for corporations, financial institutions, governments, and individuals worldwide. It operates through Global Banking & Markets, Asset & Wealth Management, and Platform Solutions segments. The Global Banking & Markets segment provides financial advisory services, including strategic advisory assignments related to mergers and acquisitions, divestitures, corporate defense activities, restructurings, and spin-offs; and relationship lending, and acquisition financing, as well as secured lending, through structured credit and asset-backed lending and involved in financing under securities to resale agreements. This segment also offers client execution activities for cash and derivative instruments; credit and interest rate products; and provision of mortgages, currencies, commodities, and equities related products, as well as underwriting services. The Asset & Wealth Management segment manages assets across various classes, including equity, fixed income, hedge funds, credit funds, private equity, real estate, currencies, and commodities; and provides customized investment advisory solutions, wealth advisory services, personalized financial planning, and private banking services, as well as invests in corporate equity, credit, real estate, and infrastructure assets. The Platform Solutions segment offers credit cards and point-of-sale financing for purchase of goods or services. This segment also provides cash management services, such as deposit-taking and payment solutions for corporate and institutional clients. The Goldman Sachs Group, Inc. was founded in 1869 and is headquartered in New York, New York.

Vericel NASDAQ:VCEL

$33.46 -1.67 (-4.75%)

Closing price 05/8/2026 04:00 PM Eastern

Extended Trading

$33.60 +0.14 (+0.42%)

As of 05/8/2026 07:43 PM Eastern

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GS, VCEL, ARGX, AZTA, and AXSM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GS, VCEL, ARGX, AZTA, and AXSM Earnings

Compare Dividends

Latest GS, VCEL, ARGX, AZTA, and AXSM Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GS, VCEL, ARGX, AZTA, and AXSM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GS, VCEL, ARGX, AZTA, and AXSM Company Descriptions

argenex NASDAQ:ARGX

Axsome Therapeutics NASDAQ:AXSM

Azenta NASDAQ:AZTA

The Goldman Sachs Group NYSE:GS

Vericel NASDAQ:VCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools